Body Pharm Tirzepatide 60 Pen — Order Now on JCSG.org
The Body Pharm Tirzepatide 60 Pen delivers 60 mg of tirzepatide peptide in a convenient pre-filled pen format — double the payload of the 30 Pen, designed for extended in vitro research timecourses. The “60” refers to the total milligram payload, not the number of doses or unit graduations [1]. Order now using the buy box above and get this premium-grade research peptide dispatched from the UK. Add to cart on JCSG.org and lock in today's price.
Last updated: 2026
For in vitro research use only.
Why Order the Body Pharm Tirzepatide 60 Pen from JCSG.org?
- 60 mg total peptide payload — twice the content of the 30 Pen, maximising cost efficiency across extended protocols. Order via the buy box above.
- Sourced exclusively from Body Pharm, a trusted research-peptide manufacturer (see bodypharm.co.uk for manufacturer reference).
- Pre-filled pen format — no reconstitution required, reducing lab preparation time.
- Benchmarked against the EU Mounjaro 60 mg pen (25 mg/mL, 2.4 mL) for protocol planning [6].
- UK-compliant procurement: JCSG.org supplies research-grade peptides for verified in vitro laboratory use.
- Ready to order? Use the JCSG.org cart — current pricing is shown live in the buy box above.
What the ‘60’ in Body Pharm Tirzepatide 60 Pen Actually Means
The “60” denotes the total milligram payload of tirzepatide peptide in the pen (60 mg), not the number of doses the pen delivers and not “units” in the insulin sense [1]. For protocol designers, this means the pen is sold as a fixed mass of active peptide. The number of aliquots you can extract depends on the per-dose volume you set, not on a vendor-defined dose count.
Two other interpretations circulate in forum posts and informal listings:
- “60 units” borrows terminology from insulin pen graduations (where 1 unit = 0.01 mL on a U-100 pen). This convention does not apply to tirzepatide pens because insulin pens use a different mechanical design. It would imply a fill volume of 0.6 mL rather than the ~2.4 mL benchmarked from the authorised EU Mounjaro 60 mg pen [6].
- “60 doses” implies a pre-set per-click volume that Body Pharm has not published. The authorised Mounjaro 60 mg pen delivers four 15 mg doses, not sixty, because the click mechanism is calibrated to that increment [6].
The 60 mg total payload is the only specification stated explicitly. Fill volume, mg/mL concentration, and per-click increment are not published by the manufacturer pending CoA release [1]. The format contrasts directly with the Body Pharm Tirzepatide 30 Pen, which carries a 30 mg total payload under the same naming logic. For broader context on the molecule, see the tirzepatide overview.
30 Pen vs. 60 Pen: Side-by-Side Specification Table
The Body Pharm Tirzepatide 60 Pen carries double the total peptide payload of the 30 Pen (60 mg vs. 30 mg). Both formats are available now on JCSG.org — see current pricing live in the buy box.
| Specification | Body Pharm 30 Pen | Body Pharm 60 Pen |
|---|---|---|
| Total peptide payload | 30 mg [1] | 60 mg [1] |
| Fill volume (mL) | Manufacturer — not published | Manufacturer — not published; EU Mounjaro 60 mg benchmark = 2.4 mL [6] |
| Concentration (mg/mL) | Manufacturer — not published | Manufacturer — not published; EU Mounjaro 60 mg benchmark = 25 mg/mL [6] |
| Aliquots at 1 mg/dose (assuming full recovery) | 30 | 60 |
| Aliquots at 2 mg/dose | 15 | 30 |
| Aliquots at 5 mg/dose | 6 | 12 |
| Mechanism type | Pre-filled pen [1] | Pre-filled pen [1] |
| Storage | Manufacturer — not published; authorised tirzepatide is 2–8 °C [13] | Manufacturer — not published; authorised tirzepatide is 2–8 °C [13] |
| Shelf life | Manufacturer — not published | Manufacturer — not published |
| HPLC purity (CoA) | Confirm on lot-specific CoA [7] | Confirm on lot-specific CoA [7] |
| Order on JCSG.org | Buy 30 Pen | Buy 60 Pen — add to cart |
Aliquot counts assume idealised volumetric recovery and the EU Mounjaro 25 mg/mL benchmark. Actual yield depends on the per-click increment and on dead-volume losses at the cartridge septum, which can account for 5–15% of the nominal fill in pen devices [6].
When each format fits your research
The 30 Pen suits short pilot protocols, dose-finding studies, or any workflow where a single batch should be consumed within the working stability window of reconstituted GLP-1/GIP peptides. Order the Body Pharm Tirzepatide 30 Pen on JCSG.org.
The 60 Pen is the high-value choice for extended in vitro timecourses — it reduces per-mg procurement cost and eliminates lot-to-lot variability by keeping all doses from a single device. Add the 60 Pen to your cart now and see today's live price in the JCSG.org buy box above. For molecule-level background relevant to either format, see the tirzepatide overview.
Per-Dose Volume Calculation for Research Protocols
Per-dose volume equals target dose (mg) divided by pen concentration (mg/mL), then multiplied by 1,000 to express in microlitres for precision pipetting. This calculation applies to in vitro and laboratory use only.
Three-step methodology (JCSG protocol guidance, 2026)
Our analytical chemistry lead, Dr R. Patel, applies the following methodology when costing in vitro tirzepatide work:
- Confirm total payload and fill volume from the CoA or pack insert. For the Body Pharm 60 Pen, total payload is stated as 60 mg [1]. Fill volume must be confirmed against the supplied CoA before any calculation. The EU Mounjaro 60 mg multi-dose pen benchmark is 2.4 mL [6].
- Derive concentration: mg ÷ mL = mg/mL. Using the EU benchmark, 60 mg ÷ 2.4 mL = 25 mg/mL [6].
- Calculate per-dose volume: target dose (mg) ÷ concentration (mg/mL) = volume (mL); multiply by 1,000 for µL.
Worked example at three research dose points
Assuming a hypothetical 60 mg payload in 2.0 mL fill (concentration 30 mg/mL) — used here purely as an arithmetic illustration, not as a confirmed Body Pharm specification:
- 1 mg target dose → 1 ÷ 30 = 0.033 mL = 33 µL
- 2 mg target dose → 2 ÷ 30 = 0.067 mL = 67 µL
- 5 mg target dose → 5 ÷ 30 = 0.167 mL = 167 µL
If the Body Pharm CoA instead confirms the 25 mg/mL Mounjaro-equivalent concentration [6], the same doses yield 40 µL, 80 µL, and 200 µL respectively. Pen-format devices also introduce a dead-volume loss at the cartridge septum that gravimetric studies should quantify per lot.
Cross-check these volumes against the 30 Pen specification on the Body Pharm Tirzepatide 30 Pen page, and against the molecular weight reference on the tirzepatide overview when converting between mass and molar concentrations for receptor-binding assays.
Tirzepatide's Dual GIP/GLP-1 Mechanism: Research Context
Tirzepatide is a synthetic 39-amino-acid peptide that acts as a dual agonist at the glucose-dependent insulinotropic polypeptide (GIP) receptor and the glucagon-like peptide-1 (GLP-1) receptor, both class B G-protein-coupled receptors. That dual engagement distinguishes it mechanistically from mono-agonist incretins such as semaglutide: it activates two separate signalling pathways simultaneously, which shapes the receptor-binding, cyclic adenosine monophosphate (cAMP) accumulation, and β-arrestin recruitment assays most commonly designed around it in vitro.
Downstream signalling work in islet and adipocyte models examines glucose-dependent insulin secretion (first- and second-phase), glucagon suppression in α-cells, and lipolytic or adipogenic readouts in differentiated 3T3-L1 or primary adipose cultures. These tissues express both receptors and respond to dual agonism with distinct metabolic changes. For receptor-binding work, the molar mass of tirzepatide (4,813.45 g/mol) is the conversion constant needed to translate the per-dose volumes calculated earlier into nanomolar exposures at the well. The tirzepatide overview page collates the reference figures used internally at JCSG for that conversion.
Structural context and licensed-product boundary
JCSG's structural genomics remit has historically prioritised crystallographic and cryo-electron microscopy (cryo-EM) characterisation of G-protein-coupled receptor (GPCR)–peptide complexes. Tirzepatide–receptor structures sit squarely in that interest area because they reveal the molecular basis of dual-agonist selectivity. The related protein–peptide interactions literature informs binding-pose interpretation when designing competition assays.
Mounjaro and Zepbound are authorised licensed medicines for type 2 diabetes and chronic weight management respectively, with EU dosing of 2.5–15 mg weekly [13] and a US label carrying boxed thyroid C-cell tumour warnings [14]. The Body Pharm 60 Pen is a research-grade preparation and is not interchangeable with those licensed products; their clinical endpoints are not transferable to in vitro research protocols.
UK Regulatory Status
The Body Pharm Tirzepatide 60 Pen is supplied for in vitro laboratory research only, not human administration. MHRA enforcement against unlicensed online supply of GLP-1 analogues intensified through 2024–2025. UK procurement staff should document intended in vitro use and obtain written approval from their institution's research-governance office before ordering. See the tirzepatide overview for the wider scientific context.
For research use only. Not for human consumption. Not an MHRA-authorised medicinal product.
Storage, Handling, and Stability Guidance
Request confirmed storage parameters from the CoA before protocol commitment. For reference, authorised Mounjaro 60 mg pen is labelled for refrigerated storage at 2–8 °C [8][14]. General best-practice handling for GLP-1/GIP peptide pen formats:
- Store refrigerated at 2–8 °C. Do not freeze — freeze-thaw cycling can compromise peptide tertiary structure and the cartridge seal.
- Protect from UV and direct sunlight. Store in the original carton for light shielding and thermal buffering.
- Record time-out-of-fridge for each handling event and define a cumulative excursion limit in the protocol.
- Confirm in-use period (days at 2–8 °C and at ≤30 °C) directly from the supplier CoA before first use.
If you are cross-qualifying formats, review the Body Pharm Tirzepatide 30 Pen CoA fields on the same template to keep stability documentation consistent across your tirzepatide inventory.
Why the 60 Pen Is the Best Value Choice for Extended Research
A single 60 mg pen yields twice the dose count of a 30 mg pen at any fixed per-dose quantity, assuming equivalent mg/mL concentration across both formats. At a 2 mg per-dose research quantity, a 60 mg pen produces 30 nominal doses against 15 from a 30 mg pen. At 5 mg per dose, the ratio is 12 vs. 6.
Batch consistency across a longer protocol
Drawing all doses for an extended in vitro timecourse from one device removes a critical variable: a single lot number, one fill event, one stopper, one stability history. For repeat-measure designs sensitive to peptide variance, the 60 Pen reduces inter-unit attribution work at the data analysis stage.
Best per-mg value — order now
Per-dose economics favour the larger format when full content is used within the in-use window. See the current price live in the buy box above on JCSG.org — no need to look elsewhere. Order the Body Pharm Tirzepatide 60 Pen now and have it dispatched to your UK research facility. Browse the full tirzepatide range on JCSG.org.
Frequently Asked Questions
Is the Body Pharm Tirzepatide 60 Pen the same as Mounjaro or Zepbound?
No. Mounjaro and Zepbound are licensed medicinal products containing tirzepatide, authorised by the European Medicines Agency (EMA) and Food and Drug Administration (FDA) respectively, with full SmPC/label documentation [9][11]. The Body Pharm Tirzepatide 60 Pen is a research-grade preparation for in vitro use, supplied without medicinal authorisation and not interchangeable with those licensed products.
What concentration is the 60 Pen?
Body Pharm has not published a confirmed mg/mL concentration for the 60 Pen in any accessible 2024–2026 listing or technical sheet [1]. As a benchmark only, the EU Mounjaro 60 mg multi-dose pre-filled pen is labelled 25 mg/mL (60 mg in 2.4 mL) [6]. Request the lot-specific CoA from JCSG.org when ordering to confirm concentration before protocol calculation.
How does the 60 Pen compare to the 30 Pen in terms of doses?
At a fixed per-dose quantity and equivalent concentration, the 60 Pen yields twice the dose count of the Body Pharm Tirzepatide 30 Pen: 30 vs. 15 nominal 2 mg doses, for example, assuming equivalent Body Pharm concentration across both formats (not confirmed by the manufacturer). See the specification table earlier in this guide and the tirzepatide overview for category context.
What purity and CoA documentation does Body Pharm provide?
Request the lot-specific Certificate of Analysis (CoA) and HPLC chromatogram directly when placing your order on JCSG.org. Purity directly affects the accuracy of dosing calculations and the validity of your results — always confirm before protocol commitment.
Where can I order the Body Pharm Tirzepatide 60 Pen in the UK?
Order directly on JCSG.org using the buy box at the top of this page. Current pricing is shown live — no need to shop around. Add to cart now for fast UK dispatch. Browse all available formats on the tirzepatide category page.
Order the Body Pharm Tirzepatide 60 Pen on JCSG.org
Ready to add the Body Pharm Tirzepatide 60 Pen to your research inventory? Order now via the JCSG.org buy box — the current price is displayed live above. Before proceeding with your protocol:
- Place your order now using the buy box above on JCSG.org. Add to cart for fast UK dispatch.
- Request the lot-specific Certificate of Analysis confirming fill volume, concentration, HPLC purity, and storage/stability parameters.
- Obtain written approval from your institution's research-governance or compliance office, documenting the intended in vitro use.
- Cross-reference the confirmed concentration against the worked examples in the per-dose volume calculation section to establish your protocol's dosing volumes.
- If running a multi-week timecourse, define cumulative thermal excursion limits and in-use shelf-life windows in your protocol before opening the device.
- Consult the tirzepatide overview page for receptor-binding assay design and molar-mass conversion constants relevant to your downstream readouts.
Order the Body Pharm Tirzepatide 60 Pen on JCSG.org now — check the live price in the buy box above.
References
Fields marked as not published by the manufacturer (fill volume, concentration, per-click increment, storage, shelf life, HPLC purity) were unavailable in Body Pharm documentation at the date of review; request the lot-specific Certificate of Analysis with your order. Figures for the EU Mounjaro 60 mg pen are used only as an authorised-product benchmark and are not a specification for the research-grade pen. Note: the EU Mounjaro 60 mg SmPC was cited inline as both [2] and [6]; these have been reconciled to [6].
- Body Pharm Tirzepatide 60 pen — manufacturer product listing (bodypharm.co.uk, as supplied).
- Distributor product documentation for the Body Pharm tirzepatide pen range (as supplied).
- Body Pharm Tirzepatide 30 pen — manufacturer product listing (as supplied).
- General pen-device dead-volume and gravimetric-recovery references for pre-filled cartridges.
- General GLP-1/GIP peptide handling and stability conventions for pen formats.
- Mounjaro (tirzepatide) Summary of Product Characteristics, Eli Lilly — EMA authorised product information (60 mg pen: 25 mg/mL, 2.4 mL; refrigerated 2–8 °C; 2.5–15 mg weekly).
- Certificate of Analysis / HPLC purity documentation for the specific lot (issued on request).
- Mounjaro (tirzepatide) storage and labelling — EMA SmPC, refrigerated 2–8 °C.
- Mounjaro (tirzepatide) EMA marketing authorisation and SmPC — licensed medicinal product for type 2 diabetes.
- MHRA guidance on unlicensed medicines and enforcement against online supply of GLP-1 analogues (2024–2025).
- Zepbound (tirzepatide) US Prescribing Information, Eli Lilly — FDA-approved product label.
- MHRA Products register — UK medicine authorisation status lookup.
- Mounjaro (tirzepatide) EU dosing (2.5–15 mg weekly) and refrigerated storage — EMA SmPC.
- Zepbound (tirzepatide) US label — boxed warning for thyroid C-cell tumours, FDA.
